Last reviewed · How we verify

recombinant human BNP(1-32)

VA Office of Research and Development · FDA-approved active Small molecule

Recombinant human BNP(1-32) is a truncated B-type natriuretic peptide that activates natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and inhibit the renin-angiotensin-aldosterone system.

Recombinant human BNP(1-32) is a truncated B-type natriuretic peptide that activates natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and inhibit the renin-angiotensin-aldosterone system. Used for Acute decompensated heart failure.

At a glance

Generic namerecombinant human BNP(1-32)
Also known asnesiritide, Natrecor
SponsorVA Office of Research and Development
Drug classNatriuretic peptide
TargetNatriuretic peptide receptor-A (NPR-A)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

BNP(1-32) is a shorter, biologically active fragment of B-type natriuretic peptide that binds to natriuretic peptide receptor-A (NPR-A) on vascular smooth muscle and endothelial cells. This activation triggers increased cGMP production, leading to vasodilation, reduced sodium reabsorption, and decreased sympathetic nervous system activity. The net effect is improved hemodynamics and reduced cardiac workload in heart failure patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: